Evidence map›Paper›PMID 33225276›Full record

ArticleBrain communications2020

A potential role of fatty acid binding protein 4 in the pathophysiology of autism spectrum disorder.

Motoko Maekawa, Tetsuo Ohnishi, Manabu Toyoshima, Chie Shimamoto-Mitsuyama, Kei Hamazaki, Shabeesh Balan, Yuina Wada, Kayoko Esaki, Shu Takagai, Kenji J Tsuchiya and 14 more

Open access · goldAbstract read
In one paragraph

Article in Brain communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Editorial.Brain communications · 2021
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 1 country.

Motoko MaekawaLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.
Tetsuo OhnishiLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.
Manabu ToyoshimaLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.
Chie Shimamoto-MitsuyamaLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.
Kei HamazakiDepartment of Public Health, Faculty of Medicine, University of Toyama, Toyama, Japan.
Shabeesh BalanLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.ORCID 0000-0002-1098-1290
Yuina WadaLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.
Kayoko EsakiLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.
Shu TakagaiDepartment of Child and Adolescent Psychiatry, Hamamatsu University School of Medicine, Shizuoka, Japan.
Kenji J TsuchiyaResearch Center for Child Mental Development, Hamamatsu University School of Medicine, Shizuoka, Japan.
Kazuhiko NakamuraDepartment of Psychiatry, Hirosaki University School of Medicine, Aomori, Japan.
Yasuhide IwataDepartment of Psychiatry and Neurology, Fukude Nishi Hospital, Shizuoka, Japan.
Takahiro NaraDepartment of Rehabilitation, Miyagi Children's Hospital, Miyagi, Japan.
Yoshimi IwayamaLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.
Tomoko ToyotaLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.
Yayoi NozakiLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.
Hisako OhbaLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.
Akiko WatanabeLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.
Yasuko HisanoLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.
Shigeru MatsuokaDepartment of Clinical Pharmacology, Faculty of Medicine, Oita University, Oita, Japan.
Masatsugu TsujiiSchool of Contemporary Sociology, Chukyo University, Aichi, Japan.
Norio MoriDepartment of Psychiatry and Neurology, Fukude Nishi Hospital, Shizuoka, Japan.
Hideo MatsuzakiResearch Center for Child Mental Development, University of Fukui, Fukui, Japan.
Takeo YoshikawaLaboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Saitama, Japan.ORCID 0000-0003-2791-6679
RIKEN Center for Brain Science · JPHamamatsu University School of Medicine · JPChukyo University · JPHirosaki University · JPMiyagi Children's Hospital · JPOita University · JPUniversity of Fukui · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autism spectrum disorder is a neurodevelopmental disorder characterized by difficulties in social communication and interaction, as well as repetitive and characteristic patterns of behaviour. Although the pathogenesis of autism spectrum disorder is unknown, being overweight or obesity during infancy and low weight at birth are known as risks, suggesting a metabolic aspect. In this study, we investigated adipose tissue development as a pathophysiological factor of autism spectrum disorder by examining the serum levels of adipokines and other metabolic markers in autism spectrum disorder children (

Indexed as

adipose tissueearly childhoodearly diagnostic biomarkerfunctional variantspolyunsaturated fatty acid (PUFA)

Identifiers

PMID33225276
PMCPMC7667725
OpenAlexW3085574365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.